Reflect Wellness and Aesthetics Review: What Its GLP-1 Documentation Establishes

A medication menu can establish what a practice advertises without establishing how well its treatment works. That distinction is central to Reflect Wellness and Aesthetics, which publishes local prices for compounded semaglutide and tirzepatide, describes monthly monitoring and offers several vitamin-containing combinations. Its documentation gives prospective patients concrete information to investigate. It does not turn research on studied medications into evidence for Reflect’s own compounded preparations, combination products or clinical results.

This review examines public documentation consulted October 19, 2026, separating service descriptions from clinical evidence and unresolved questions. Reflect describes two different care arrangements: treatment through its Tennessee practice and a national program involving independent providers. That separation matters when interpreting who evaluates patients, who prescribes, which pharmacy fills an order and which prices apply. The goal is not to recommend a medication, but to identify what is documented and what still needs confirmation before enrollment.

At a glance

Two care arrangements: Reflect’s clinicians provide Tennessee clinic and Tennessee telehealth care; independent providers assess patients in the national program, where Reflect says it does not prescribe.
Sources: [16]
Local injectable prices: Tennessee cash-pay prices are $25–$125 per week for compounded semaglutide and $75–$175 per week for compounded tirzepatide, depending on clinician-set tiers. Each lists a $10 take-home fee with no stated frequency.
Sources: [13] [7] [15]
Documented monitoring: Reflect describes an initial health-history consultation and monthly visits. The semaglutide listing mentions baseline screening without naming specific laboratory tests.
Sources: [15] [13]
Compounding evidence boundary: Reflect describes patient-specific prescriptions from state-licensed 503A compounding pharmacies. Compounded preparations are not FDA approved; pharmacy registration does not establish product approval.
Sources: [13] [11] [1]
Purchase terms remain important: Published terms defer specific cancellation, refund and no-show rules to purchase or booking documents; separate clinical agreements govern care.
Sources: [16]

Start with the care arrangement, not the national label

Reflect identifies clinics in Murfreesboro and Franklin, Tennessee, and says Dr. Brandon Hardin owns and leads the practice. Weight management is one of five advertised service categories, alongside peptides, hormone therapy, aesthetics and IV therapy. The website names Danelle Farmer, NP, as a Murfreesboro weight-management provider and Michelle Sloan, NP, as a Franklin provider. It describes both as board-certified nurse practitioners; those credential claims were not independently verified for this review.

The practice says its own licensed providers deliver care at its Tennessee locations and through Tennessee telehealth visits. It also advertises medication delivery to patients across Tennessee. Its national program is different: an independent provider network, accessed through a partner telehealth platform, conducts medical assessments. Reflect explicitly says it does not prescribe through that program or control those providers’ medical judgment. These are distinct responsibilities, not interchangeable descriptions of one clinic service.

The consulted documentation does not identify the national platform, independent network or dispensing pharmacies by name. It also does not provide a state-by-state availability list. Reflect’s terms say programs and medications vary by state, so “nationwide” should not be read as guaranteed access everywhere. Our guide to what public provider documents can prove explains why a service description is useful evidence of an advertised arrangement, but not independent verification of every organization involved.

Sources: [11] [15] [16]

What Reflect actually lists—and what those listings do not prove

Reflect describes compounded semaglutide as a provider-guided GLP-1 injection program with monthly visits and ongoing monitoring. Its product page identifies a weekly self-administered injection and says the clinician explains how it is supplied and injected during consultation. Compounded tirzepatide is described as a dual GLP-1 and GIP injection program dosed and monitored by a licensed provider. These statements document the advertised route and oversight model, not independently measured effectiveness.

Two Tennessee-only offerings add ingredients: SkinT pairs compounded tirzepatide with B12 and L-carnitine in one weekly injection program, while Xtra Skinny pairs compounded semaglutide with those ingredients. Their listings describe monthly clinician visits. The consulted materials do not establish clinical outcomes for either combination or demonstrate that adding those ingredients improves results. A branded program name and a shared ingredient name do not make different formulations interchangeable evidence subjects.

FDA explains that compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. That status alone does not prove clinical inequivalence or settle whether a particular provider delivers appropriate care. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Our explanation of approved medicines and compounded preparations develops that distinction without treating pharmacy registration as product approval.

Sources: [13] [7] [8] [9] [1]

Read the local price menu as a menu, not a complete bill

Reflect publishes unusually specific local price ranges, but their boundaries matter. The menu is for cash-pay treatment at Tennessee clinics; national telehealth packages are priced separately. Semaglutide and tirzepatide each have six clinician-set tiers, with a $10 take-home fee listed on each product page. The fee’s frequency is not specified. Weekly prices should not be presented as calendar-month charges, and a range’s lowest amount is not a promise of every patient’s starting price.

Reflect says it is direct-pay, does not provide insurance coverage for the program and confirms the full plan cost, including any take-home fee, before treatment begins. Membership is advertised as optional, never required. The semaglutide page promotes “up to 15% off with membership,” but the consulted documentation does not establish membership cost or the conditions for the maximum discount. That prevents a reliable net-price or savings calculation.

The table preserves the published local units rather than inventing monthly totals. It remains unclear whether every quoted rate includes consultation, laboratory testing, injection supplies or shipping. The documentation also does not establish a billing interval, required prepayment or minimum commitment. A useful written estimate would identify the selected program, applicable tier, included services, take-home fee frequency and any recurring charges separately from the clinical visit schedule.

Published Tennessee clinic cash-pay injection programs; national package prices are separate
Program and presentation	Published weekly price	Material conditions
Compounded semaglutide injection	$25–$125	Six clinician-set tiers; $10 take-home fee; fee frequency unspecified
Compounded tirzepatide injection	$75–$175	Six clinician-set tiers; $10 take-home fee; fee frequency unspecified
SkinT: compounded tirzepatide with B12 and L-carnitine, weekly injection	$85–$185	Six clinician-set tiers; Tennessee clinics only; monthly visits
Xtra Skinny: compounded semaglutide with B12 and L-carnitine, weekly injection	$35–$100	Five clinician-set tiers; Tennessee clinics only; monthly visits

Sources: [13] [7] [15] [11] [8] [9]

Consultation and follow-up are documented, but not fully specified

Reflect describes an initial consultation with a licensed clinician to review health history and goals and determine whether a program fits the patient’s plan. Its semaglutide listing includes “Baseline health screening at consult,” without identifying a laboratory panel. A screening statement therefore should not be expanded into a promise that particular blood tests are ordered, included in the price or reviewed on a particular timetable.

Monthly visits are a clear feature of the local program description. Reflect says clinicians adjust treatment within program tiers according to how the patient is doing, rather than on a fixed schedule. This documents an intention to individualize follow-up, but it does not establish visit length, between-visit availability or response time. NIDDK describes follow-up as attention to tolerance and response; an appointment schedule alone cannot demonstrate the quality of that assessment.

The terms require users to be at least 18 to use the site, book services or submit intake information. That is not a complete medication eligibility policy. The consulted documentation does not publish full clinical criteria or contraindication screening. Prospective patients can prepare questions about medicines, supplements, allergies and pregnancy plans, consistent with NIDDK guidance, while leaving treatment decisions to the clinician. The national assessment explicitly does not guarantee a prescription.

Sources: [15] [13] [16] [2]

Clinical trials are not Reflect outcome reports

STEP 1 studied subcutaneous semaglutide in adults with obesity, or overweight plus a weight-related condition, without diabetes, over 68 weeks. Both groups received lifestyle intervention. The studied 2.4 mg weekly arm had mean weight change of −14.9%, versus −2.4% with placebo; that dose identifies the research arm, not patient instructions. Gastrointestinal events led to discontinuation in 4.5% versus 0.8%. Novo Nordisk funded the trial. It was not a study of Reflect’s compounded semaglutide or vitamin-containing combination.

SURMOUNT-1 studied subcutaneous tirzepatide over 72 weeks in adults with obesity, or overweight plus a weight-related complication, excluding diabetes. Mean weight changes were −15.0%, −19.5% and −20.9% for the studied 5, 10 and 15 mg weekly groups, respectively, versus −3.1% with placebo. Gastrointestinal events were most common; adverse-event discontinuations were 4.3%, 7.1% and 6.2%, respectively, versus 2.6%. Eli Lilly funded the trial. These research groups are not dosing recommendations.

Neither trial establishes outcomes for Reflect, its dispensing pharmacies or its compounded combinations. Comparing their percentages also does not create a randomized head-to-head comparison. The consulted Reflect materials do not provide a provider-specific outcomes dataset with follow-up duration, participant numbers and discontinuation information. That is an evidence gap, not proof of poor results. Our guide on why a clinical trial is not a company performance report explains how to keep these different claims separate.

Sources: [3] [4] [13] [7] [8] [9]

Pharmacy and delivery claims need a named handoff

Reflect states that it is not a pharmacy. It attributes prescribing to licensed medical providers and fulfillment to U.S.-licensed, FDA-registered pharmacies, including 503A compounding pharmacies for compounded medications. Its program pages describe patient-specific prescriptions from a state-licensed 503A pharmacy. National terms say the provider network selects the compounding pharmacy when a prescription is issued. These are provider statements; this review did not independently verify pharmacy licensing, registration or the identity of a particular dispenser.

For patients outside Tennessee, the semaglutide page advertises an online assessment and home delivery where available. It does not establish a clinical-review deadline, dispatch date or arrival window. Nor do the consulted materials specify the carrier, cold-chain procedures or responsibility for damaged or missing shipments. Before purchase, identifying the dispensing pharmacy and the contact responsible for delivery problems would make the handoff more concrete than a general promise of home delivery.

FDA explicitly recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. It also reports measurement and administration errors involving compounded medications, some associated with hospitalization. Those reports do not supply a Reflect-specific event rate or automatically establish causation. Reflect’s promised injection education is relevant, but readers should resolve instructions with their prescriber or pharmacist rather than calculate doses from a review.

Sources: [11] [13] [16] [1]

The wider menu should remain separate from the core program

Reflect lists in-person B12 and L-carnitine injections at $10 each, available at Franklin and Murfreesboro during consultation or follow-up without another appointment. A lipotropic injection is listed at $20 under similar visit arrangements. Its specific blend is deferred to consultation rather than enumerated on the page. These are additional advertised services, not evidence that they are necessary components of GLP-1 treatment or that their cost is included in a weekly program price.

The menu also describes prescription phentermine tablets at $30 for 30 tablets, with suitability reviewed by the clinician and monitoring alongside program visits. Thirty tablets should not be relabeled a month’s supply. Compounded prescription ondansetron tablets are advertised at $6.99 for 15 or $10.99 for 30, Tennessee clinics only. Reflect presents these as medications a clinician may prescribe alongside weight management, not automatic inclusions or prescriptions every patient receives.

The B12 and L-carnitine pages leave some ambiguity about access: they describe add-ons, while their FAQs permit obtaining them without a weight-management program. That calls for clarification about booking, not a conclusion that the services are unavailable. More broadly, an extensive menu should not substitute for evidence about a proposed formulation. Our guide to ingredient names, formulations and routes explains why evidence questions follow the actual preparation rather than its marketing category.

Sources: [14] [10] [6] [5] [12] [3] [4]

Documents to obtain before paying

Reflect’s published terms describe themselves as a good-faith operational draft not yet reviewed by an attorney. They also say separate clinical consents and agreements govern medical care. Specific refund, cancellation and no-show conditions presented at purchase or booking control over the general summary. Consequently, the public terms do not establish a universal cancellation deadline, refund entitlement or minimum commitment. Cancellation and refund should be treated as separate questions when requesting the applicable agreement.

Payment arrangements also differ by channel: national payments use a third-party processor, while in-clinic payments use clinic systems. Reflect says its site does not store full payment-card details. The documentation does not establish automatic renewal or billing frequency. Requesting the actual checkout terms, an itemized quote and the treating organization’s identity would help connect the advertised weekly rate to the payment being authorized, without assuming that monthly clinical follow-up means monthly billing.

Website forms, messages and booking tools are expressly not monitored for urgent medical needs. The consulted materials do not establish response-time commitments or after-hours clinical access. Reflect also says marketing-text consent is not a purchase condition and permits opting out by replying STOP. Before enrolling, patients should obtain the routine clinical contact route, pharmacy contact and instructions for urgent concerns; marketing messaging and appointment tools are not evidence of an urgent-care service.

Sources: [16]

Questions & answers

Would Reflect itself prescribe if I enroll outside Tennessee?

Not under the national arrangement described in its terms. Reflect says an independent provider network conducts assessments through a partner platform, and that Reflect does not prescribe or control those clinicians’ judgment. Availability varies by state, and completing an assessment does not guarantee a prescription. Ask which organization will treat you and which pharmacy would fill an approved prescription.

Sources: [16]

Is the $25 weekly semaglutide price available nationally?

The documented $25–$125 weekly range is a Tennessee clinic cash-pay price for compounded semaglutide across six clinician-set tiers. National packages are priced separately. The local page also lists a $10 take-home fee without specifying how often it applies. Confirm the complete applicable charge rather than treating the lowest tier as a national offer or an all-inclusive bill.

Sources: [13] [15]

Does Reflect require a membership or accept insurance for this program?

Reflect advertises membership as optional and describes the program as direct-pay rather than insurance-covered. Its semaglutide page promotes up to 15% off with membership, but the consulted documentation does not establish membership cost or the conditions for the maximum discount. Ask for both member and nonmember itemized quotes before judging whether membership changes the total cost favorably.

Sources: [11] [13] [15]

Are baseline laboratory tests and monthly visits included?

Monthly visits and baseline health screening are advertised, but the consulted pages do not identify specific laboratory tests or establish whether all visits, tests and supplies are included in every listed rate. Ask which screening is required, who orders and reviews it, and what is charged separately. Reflect says the clinician confirms the full plan cost before treatment starts.

Sources: [13] [15]

Do published semaglutide and tirzepatide trials validate SkinT or Xtra Skinny?

No. The cited trials studied particular subcutaneous medication regimens, not Reflect’s vitamin-containing compounded combinations. SkinT pairs compounded tirzepatide with B12 and L-carnitine; Xtra Skinny pairs compounded semaglutide with those ingredients. Their listings establish what Reflect advertises, not that the added ingredients improve outcomes. The trials also do not predict an individual patient’s results or establish Reflect’s performance.

Sources: [8] [9] [3] [4]

Can I determine my cancellation and refund rights from the public terms?

Not completely. Reflect says the specific conditions presented when purchasing or booking control over its general summary, and separate clinical agreements govern care. The public documentation does not establish a universal refund policy, cancellation deadline or renewal schedule. Obtain those terms before payment, including what happens after an assessment or prescription, and do not assume that canceling automatically returns money already paid.

Sources: [16]

Our assessment

Reflect provides useful documentary detail about its Tennessee locations, named clinicians, compounded injection programs, local price tiers and monthly monitoring. Its explicit separation of Tennessee care from independent national prescribing is especially important. Those disclosures make a focused pre-enrollment conversation possible, but they do not establish provider-specific effectiveness or validate its combination preparations. The most consequential unresolved items are the national organizations and pharmacies involved, complete program costs, laboratory requirements, delivery procedures and purchase-specific cancellation terms. A reasonable next step is to request a written plan identifying the treating entity, actual formulation, dispensing pharmacy, included services and payment obligations. Evaluate those answers alongside the clinical rationale for a compounded preparation, rather than treating medication trial results or pharmacy-registration language as an endorsement of Reflect.

Visit Reflect Wellness and Aesthetics’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Reflect Wellness and Aesthetics Review: What Its GLP-1 Documentation Establishes

At a glance

01Start with the care arrangement, not the national label

02What Reflect actually lists—and what those listings do not prove

03Read the local price menu as a menu, not a complete bill

04Consultation and follow-up are documented, but not fully specified

05Clinical trials are not Reflect outcome reports

06Pharmacy and delivery claims need a named handoff

07The wider menu should remain separate from the core program

08Documents to obtain before paying

Questions & answers

Our assessment

Sources & documentation

Continue reading

Start with the care arrangement, not the national label

What Reflect actually lists—and what those listings do not prove

Read the local price menu as a menu, not a complete bill

Consultation and follow-up are documented, but not fully specified

Clinical trials are not Reflect outcome reports

Pharmacy and delivery claims need a named handoff

The wider menu should remain separate from the core program

Documents to obtain before paying